Detalhe da pesquisa
1.
Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML.
Blood Adv
; 6(17): 5132-5145, 2022 09 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35728048
2.
Pharmacokinetic, pharmacodynamic and covariate analysis of subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma.
Clin Pharmacokinet
; 51(12): 823-9, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-23018466